Abstract #2477

Amide CEST at 7T: A possible biomarker for response to neoadjuvant chemotherapy in breast cancer

Erwin Krikken¹, Moritz Zaiss², Vitaliy Khlebnikov¹, Hanneke W.M. van Laarhoven³, Dennis W.J. Klomp¹, and Jannie P. Wijnen¹

¹Radiology, University Medical Center Utrecht, Utrecht, Netherlands, ²Deutsches Krebforschungszentrum, Heidelberg, Germany, ³Medical Oncology, Academic Medical Center Amsterdam, Amsterdam, Netherlands

Neoadjuvant chemotherapy has an important role in the treatment of breast cancer and the need for early detection of treatment response is high. As a non-invasive method able to predict treatment response is lacking, we investigated the feasibility of using amide CEST MRI at 7T as a biomarker. Six patients were included after informed consent was given. The ATP signal was robust and repeatedly detectable in the same patient. Significant differences were seen in amide signal before and after the first cycle of chemotherapy.

How to access this content:

For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.

After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.

After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.

Click here for more information on becoming a member.